Immuneering Corporation (IMRX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
245 Main Street
Cambridge, MA 02142
United States of America (the)
Phone
617 500 8080
Website
Sector
Healthcare
Industry
Biotechnology
Employees
54
First IPO Date
July 30, 2021
| Name | Title | Pay | Year Born |
| Benjamin J. Zeskind | Co-Founder, President, Chief Executive Officer & Director | 1.08M | 1983 |
| Robert J. Carpenter | Co-Founder & Chair Emeritus | 45,000 | 1946 |
| Harold E. Brakewood | Chief Business Officer | 579,769 | 1966 |
| Igor Matushansky | Chief Medical Officer | 656,780 | 1973 |
| Michael D. Bookman | Chief Legal Officer & Secretary | 757,560 | 1987 |
| Brett Hall | Chief Scientific Officer | 999,752 | 1969 |
| Paula George | Director of Accounting & Operations and Assistant Corporation Controller | 0 | N/A |
| Peter King | Head of Discovery & Vice President | 0 | N/A |
| Leah R. Neufeld | Chief People Officer | 0 | 1972 |
| Courtney Dugan | VP and Head of Investor Relations & Corporate Communications | 0 | N/A |
| Mallory Morales | Senior VP of Finance, Chief Accounting Officer & Treasurer | 0 | 1984 |
| Praveen Nair | Head of Translational Pharmacology & Vice President | 0 | N/A |
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.